Get the Stockscreener App
54.37
0.80%
0.43
Pre-market:
55.25
0.88
+1.62%
Biomarin Pharmaceutical Inc stock is traded at $54.37, with a volume of 2.71M.
It is up +0.80% in the last 24 hours and down -5.51% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$53.94
Open:
$53.85
24h Volume:
2.71M
Relative Volume:
1.28
Market Cap:
$10.44B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
20.21
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
-0.24%
1M Performance:
-5.51%
6M Performance:
-24.01%
1Y Performance:
-22.93%
1-Day Range:
$53.62
$55.18
1-Week Range:
$52.94
$56.07
52-Week Range:
$52.93
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
54.37 | 10.36B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.15 | 100.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.50 | 60.95B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.73 | 60.46B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
734.35 | 46.04B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.20 | 36.02B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
BMO Capital Reiterates a Buy on BioMarin Pharmaceutical (BMRN) - MSN
Acadian Asset Management LLC Has $1.70 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Intech Investment Management LLC Has $2.27 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Goldman Sachs Group Inc. Acquires 1,083,512 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Alliancebernstein L.P. Buys 61,594 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Cuts Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory - Yahoo Finance
New Study Results Highlight BioMarin’s VOXZOGO Efficacy in Children - Yahoo Finance
Bayforest Capital Ltd Purchases New Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Wesbanco Bank Inc. Increases Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Revenue Check: Is BioMarin Pharmaceutical Inc part of any major indexJuly 2025 Macro Moves & Consistent Return Investment Signals - خودرو بانک
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - sharewise.com
Portfolio Update: Can BioMarin Pharmaceutical Inc scale operations efficientlyChart Signals & Reliable Breakout Forecasts - خودرو بانک
Guidance Update: How does BioMarin Pharmaceutical Inc score in quality rankingsQuarterly Portfolio Review & Weekly High Return Forecasts - خودرو بانک
Published on: 2025-09-15 20:38:06 - خودرو بانک
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 9,837 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
Clearline Capital LP Decreases Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Biomarin’s Market Mismatch: Strong Fundamentals Clash With Share Price Weakness - AD HOC NEWS
HC Wainwright Begins Coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) - MarketBeat
BioMarin (BMRN): Valuation in Focus After New VOXZOGO and PALYNZIQ Study Results Boost Confidence - Sahm
Teza Capital Management LLC Makes New $723,000 Investment in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Federation des caisses Desjardins du Quebec Has $1.52 Million Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Parkman Healthcare Partners LLC Buys Shares of 277,252 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
NFJ Investment Group LLC Buys New Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Black Diamond Therapeutics (BDTX) - The Globe and Mail
28,736 Shares in BioMarin Pharmaceutical Inc. $BMRN Bought by Cinctive Capital Management LP - MarketBeat
Could Recent Clinical Progress Reshape BioMarin’s (BMRN) Long-Term Competitive Edge in Rare Diseases? - Sahm
Narrow-Moat BioMarin Supported by Voxzogo and Rare-Disease Pipeline - Morningstar
Biomarin at Morgan Stanley Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
Biomarin at Morgan Stanley Conference: Strategic Growth and Innovation - Investing.com
Graham Capital Management L.P. Takes Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Vident Advisory LLC Makes New Investment in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
AQR Capital Management LLC Purchases 1,642,206 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting - Lelezard
Are Options Traders Betting on a Big Move in BioMarin Pharmaceutical Stock? - sharewise.com
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment - Benzinga
Why BioMarin Pharmaceutical (BMRN) Stock Is Down Today - Yahoo Finance
BioMarin Says Data Showing Voxzogo's Benefits in Children With Achondroplasia - MarketScreener
This Duolingo Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma - MSN
Palo Alto Investors LP Lowers Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin’s PKU drug shows nearly 50% blood Phe reduction in teens - Investing.com Nigeria
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism - Yahoo Finance
Why is BioMarin Pharmaceutical Inc. stock going upInflation Watch & Fast Moving Market Watchlists - خودرو بانک
Canada Pension Plan Investment Board Increases Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
What is BioMarin Pharmaceutical Inc.’s book value per shareJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - خودرو بانک
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):